Revision 2 of ICH Q5A Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin comes into effect Virus contamination is a major concern for the manufacture of biotechnology products. While products derived from...
Blog
Uncategorized
Search
Categories
New ICH Q2(R2) and ICH Q14 Analytical Procedure Guidelines released
The ICH Q2 Guideline on the validation of analytical procedures applies to the analytical procedures used for release and stability testing of commercial drug substances and products. ICH Q2 has been in existence since 1993, with ICH Q2(R1) coming into effect in...
Italian Transition to EU Falsified Medicines Directive Compliance – Update
9th February 2025 is the deadline for full implementation of the EU Falsified Medicines legislation (Directive 2011/62/EU and EU Delegated Regulation 2016/161) at a national level in Italy. The law outlining the steps towards the Italian national implementation of the...
Shortlisted for a Pharma Industry Award
We are thrilled that our Regulatory Team was shortlisted for a Pharma Industry Awards -Pharma Contract Services Company of the Year 2024. Our nomination is for their excellent work on implementing a client Regulatory Information Management (RIM) System.
World Drug Safety Congress, Europe
Our Head of PV is attending the World Drug Safety Congress during 9-10th October in Amsterdam this year. This is Europe's Most Exciting Drug Safety and PV event and with over 90+ exhibitors, 300+ speakers and 1,500 PV experts in attendance, it promises to be a truly...
CPHI Milan 2024
On Oct 8-10th CPhI Milan 2024 will open its doors to over 60, 000 people. This year, our founder and CEO; Gemma Robinson and Senior Project Manager; Janet Fitzgerald will be in attendance. Pharma professionals from all around the world will converge in Milan for the...
PV Audit Strategy and Risk Assessment
From our experience, companies are falling short of their pharmacovigilance obligations with regards to strategic, tactical and operational level PV audit planning. This can lead to areas of non-compliance, risks to patient safety and inspection findings. Outlined...
Brexit Revisited – Are you prepared for the Windsor Framework?
More than 4 years after the United Kingdom’s exit from the EU in January 2020, the industry is still dealing with the impact of Brexit and the Northern Ireland Protocol. Most recently being the implementation of the Windsor Framework.
BioPharmaChem Impact 24 Conference
We were delighted to attend the 1st ever BioPharmaChem Impact 24 Conference which took place yesterday May 23rd in the beautiful surroundings of Fota Island Resort, Cork.
New Guidelines for Environmental Risk Assessment of Medicinal Products: What You Need to Know
Guidelines on the Environmental Risk Assessment (ERA) of Medicinal Products for human use EMEA/CHMP/SWP/4447/00 Rev.1 issued on the 15th February 2024 replaces EMEA/CHMP/SWP/4447/00 Corr 2 which has been in effect since 2006.
HPRA Rolls Out Revised ‘Guide to Renewal of Marking Authorisations – Human Medicines’ in Version 7: Here’s what you need to know
HPRA has updated their ‘Guide to Renewal of Marketing Authorisations-Human Medicines’ to Version 7 (AUT-G0025-7) and Acorn Regulatory has summarised the key changes.
Italian Transition to EU Falsified Medicines Directive Compliance
Discover the Italian Transition to EU Falsified Medicines Directive Compliance and rising questions about its impact on the Bollino System.
Why its better to trust Acorn Regulatory to manage your entire product lifecycle?
Discover the challenges and advantages of outsourcing various pharmaceutical services to multiple providers versus a single service provider. From managing the product lifecycle to ensuring regulatory compliance and communication between teams, find out how a cohesive approach can streamline processes and reduce costs. At Acorn Regulatory, we prioritise your product’s success with our global expertise and commitment to excellence.
EMA Addresses Stakeholder Queries
The EMA has issued Questions and Answers to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use.
Global DIA Forum for Qualified Persons for PV (Part 1)
We published Part 1 of our report on the Global DIA Forum for Qualified Persons in December 2023. If you missed it, catch up here.
FDA Urges Carbomer Reformulation
The FDA has provided a document attached to support product reformulation for products that contain Carbomer manufactured with Benzene.
MHRA Updated NIMAR Guidance to reflect Windsor Framework
Get up-to-date information about the Northern Ireland MHRA Authorised Route (NIMAR). Check out the recent MHRA Windsor Framework-aligned guidance changes to ensure the legal supply of POMs in the UK and EU. Discover how the Windsor framework will allow ‘PL GB’ packs to be sold in Northern Ireland in January 2025.
Falsified units of Ozempic pens found at wholesaling sites in UK and Europe
Warning: Falsified units of Ozempic pens found at wholesaling sites in UK and Europe, identified while scanning packs as part of FMD checks.
Labelling and packaging of human-use drugs after Windsor Framework agreement
“MHRA updates guidance for UK medicinal product labeling and packaging. Effective January 1, 2025:EU/UK joint packs not allowed in the supply chain.Medicines in the UK (including Northern Ireland) to be authorized separately by MHRA.EU Falsified Medicines Directive no longer applies; ‘UK only’ labeling required.MAHs must submit ‘UK only’ statement by December 31, 2024, with a 6-month over-sticker transition until June 30, 2025. Brought to you by Acorn Regulatory.”
HPRA Guide to labels and leaflets of Human Medicines
Stay Informed with HPRA’s Latest Guidance Updates – AUT-G0035-23 Revision | Medicinal Product Labeling Changes Simplified | Regulatory Compliance Made Easier | Get the Latest Submission Requirements”
Choosing an RMS
Choosing the right Reference Member State (RMS) for your EU procedure can be difficult, Here is some advice to consider, helping you make the choice for your company.
Marketing Authorisation Holder Responsibilities
Acorn Regulatory has worked with a number of MAHs including ‘virtual MAH’s’ to help them understand their responsibilities and develop a QMS suitable for their needs and to support them with each of these responsibilities. MA Holding entities are subject to Market Compliance Inspections by any Health Authority, in any EU country where they hold an MA. The HPRA carry out multiple MAH Market compliance inspections each year.
EU Medical Device Vigilance Reporting: FAQ
We answer some of the most frequently asked questions that we recieve from clients regarding EU Medical Device Vigilance Reporting in this article.
Responsibilities of Importers and Distributors
MDR 2017/745 has greatly expanded the responsibilities of importers and distributors. This article highlights the key responsibilities for both.
EU Medical Device Vigilance Reporting
In this article, we have provided the fundamentals for you to navigate through the EU Medical Device Vigilance Reporting system. Click to read more.
MDR: An Essential Guide for 2021
We have revised our MDR essential guide for 2020 to provide a fresh outlook on the developments of MDR in 2021. Click to read more here.
Conformity Assessment Routes Under MDR 2017/745
This article looks at the increase in requirements under MDR and provides a revised summary on Conformity Assessment Routes. Read more.
Post Market Surveillance under MDR
We provide a new perspective on the specific requirements of Post Market Surveillance (PMS) following the introduction of MDR in 2021. Read more here.
PRRC: Person Responsible for Regulatory Compliance
This revised article concentrates on the role of the Person Responsible for Regulatory Compliance (PRRC). The role of QP is a familiar one for those working in the Pharma sector, but this is the first time in European Medical Devices legislation that a person is...
EUDAMED Registration: Download our slide deck
One of our Senior MDR Regulatory Affairs Consultants, Michelle, provides you with a useful guide to ensure your successful EUDAMED registration. Read more.
Strategy
Subscribe to Our Newsletter
Sign up for our newsletter today and stay informed on the latest regulatory updates and industry insights.